## AC1-IN-1

Cat. No.: HY-145830 CAS No.: 2762422-55-7 Molecular Formula: C<sub>18</sub>H<sub>18</sub>FN<sub>5</sub>O<sub>2</sub> Molecular Weight: 355.37

Target: Adenylate Cyclase Pathway: GPCR/G Protein

Storage: Powder -20°C 3 years

> 4°C 2 years -80°C 6 months In solvent

-20°C 1 month

**Product** Data Sheet

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 25 mg/mL (70.35 mM; ultrasonic and warming and heat to 60°C)

	Solvent Mass Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.8140 mL	14.0698 mL	28.1397 mL
	5 mM	0.5628 mL	2.8140 mL	5.6279 mL
	10 mM	0.2814 mL	1.4070 mL	2.8140 mL

Please refer to the solubility information to select the appropriate solvent.

# **BIOLOGICAL ACTIVITY**

Description AC1-IN-1 is a potent and selective Adenylyl cyclase type 1 (AC1) inhibitor with an IC $_{50}$  of 0.54  $\mu$ M. AC1-IN-1 displays modest

antiallodynic effects in a mouse model of inflammatory pain. AC1-IN-1 has CNS activity  $^{[1]}$ .

IC<sub>50</sub> & Target  $IC_{50}$ : 0.54  $\mu$ M (AC1)<sup>[1]</sup>

In Vitro AC1-IN-1 (compound 38; HEK293 cells; 30  $\mu$ M, 1 hours) shows nontoxic to this human cell line<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay<sup>[1]</sup>

Cell Line:	HEK293 cells
Concentration:	30 μΜ
Incubation Time:	1 hours

	Result:	Showed nontoxic to HEK293 cells.		
In Vivo	to the 0 min (allodynic)	AC1-IN-1 (5.6 mg/kg; i.v.) displays modest, yet statistically significant, antiallodynic effects at 1 h post-treatment compared to the 0 min (allodynic) time point <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	Male and female C57BL/6N mice (complete Freund's adjuvant inflammatory pain model) $^{[1]}$		
	Dosage:	5.6 mg/kg (dissolved in 10% DMSO/10% Cremaphor/80% saline)		
	Administration:	Intravenous injection; 2 hours		
	Result:	Displayed modest, yet statistically significant, antiallodynic effects.		

### **REFERENCES**

[1]. Scott JA, et al. Optimization of a Pyrimidinone Series for Selective Inhibition of Ca2+/Calmodulin-Stimulated Adenylyl Cyclase 1 Activity for the Treatment of Chronic Pain. J Med Chem. 2022; 65(6):4667-4686.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: tech@MedChemExpress.com}$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA